Posted On: 01/16/2015 11:47:30 AM
Post# of 30066
Also of interest- the patent was filed with the World Intellectual property org.
not the US patent office.
Patent written in English and French (i.e. Geneva)
Patent description-
00154] Blood from many CTE patients and healthy control subjects will be drawn and to each subject's blood, cells of interest (e.g. lymphocytes) will be purified, exposed to various stimulants which will trigger the cells to begin the cell division or proliferation process. By looking a half-day later at the cells, the expression of a cell surface marker, CD69, known to be reflective of cell cycle initiation and proliferation will be measured. An index for each human subject in the study as the ratio of the CD69 expression level when stimulated by mitogen divided by the endogenous CD69 level, a so-called "stimulation index" (SI), will be calculated. Then, the SI on various sub-populations of blood cells will be measured. It will be
demonstrated that those with CTE will not able to enter the cell cycle as readily as the healthy control subjects. Without being bound by theory it is hypothesized that the dysfunction of the cellular regulatory machinery observed in the lymphocytes of the blood as measured by the "stimulation index," will reflect the cellular machinery in the neurons of the brain responsible for the neuro degeneration in the CTE patients.
not the US patent office.
Patent written in English and French (i.e. Geneva)
Patent description-
00154] Blood from many CTE patients and healthy control subjects will be drawn and to each subject's blood, cells of interest (e.g. lymphocytes) will be purified, exposed to various stimulants which will trigger the cells to begin the cell division or proliferation process. By looking a half-day later at the cells, the expression of a cell surface marker, CD69, known to be reflective of cell cycle initiation and proliferation will be measured. An index for each human subject in the study as the ratio of the CD69 expression level when stimulated by mitogen divided by the endogenous CD69 level, a so-called "stimulation index" (SI), will be calculated. Then, the SI on various sub-populations of blood cells will be measured. It will be
demonstrated that those with CTE will not able to enter the cell cycle as readily as the healthy control subjects. Without being bound by theory it is hypothesized that the dysfunction of the cellular regulatory machinery observed in the lymphocytes of the blood as measured by the "stimulation index," will reflect the cellular machinery in the neurons of the brain responsible for the neuro degeneration in the CTE patients.
(0)
(0)
